Location History:
- Chesire, GB (2018 - 2019)
- Macclesfield, GB (2018 - 2021)
- Castleford, GB (2017 - 2022)
- Cheshire, GB (2021 - 2024)
Company Filing History:
Years Active: 2017-2025
Title: The Innovative Contributions of Mark Milton-Edwards
Introduction
Mark Milton-Edwards, an accomplished inventor based in Castleford, GB, holds an impressive portfolio of 17 patents. His work embodies a relentless pursuit of innovation in the field of respiratory health, particularly through the development of advanced inhaler systems.
Latest Patents
Among Mark's latest inventions is an inhaler system designed to enhance user experience and health outcomes. This system consists of a use determination feature that evaluates airflow parameters during inhalation, coupled with a timing mechanism to manage notifications related to inhalation information. Another significant contribution is a sophisticated inhaler arrangement that assesses the likelihood of respiratory disease exacerbation. This system includes both usage detection and a sensor system to measure airflow, alongside a user interface for status input, allowing for enhanced patient monitoring and care management.
Career Highlights
Throughout his career, Mark has collaborated with esteemed organizations such as Norton (Waterford) Limited and Teva Pharmaceutical Industries Limited. His diverse experiences have been influential in shaping his innovative approaches to respiratory healthcare solutions.
Collaborations
Mark has worked alongside talented colleagues such as Michiel Ullmann and Guilherme Safioti. These collaborations have undoubtedly contributed to refining his inventive processes and expanding the impact of his work in the medical field.
Conclusion
Mark Milton-Edwards continues to be a significant figure in the realm of innovation, utilizing his expertise to develop technologies that improve the management of respiratory conditions. His dedication to advancing inhaler technology not only showcases his inventive spirit but also signifies a commitment to enhancing patient health outcomes.